Phase 1 dose-escalation, dose-expansion trial of intratumoral HER2-and HER3-primed dendritic cells injections for the treatment of early-stage TNBC and HR low positive breast cancer: DecipHER trial

被引：0
|
作者：
Costa, Ricardo L.
Childress, Jennifer A.
Abraham, Edith
Farrell, Carly
Mo, Qianxing
Jameel, Zena
Muller, Aixa Elena Soyano
Lee, Kimberley T.
Hoover, Susan
Kiluk, John
Weinfurtner, Robert J.
Lee, Marie Catherine
Laronga, Christine
Khakpour, Nazanin
Han, Hyo S.
Khong, Hung T.
Soliman, Hatem Hussein
Czerniecki, Brian J.
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS629
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
    Banerji, Udai
    van Herpen, Carla M. L.
    Saura, Cristina
    Thistiethwaite, Fiona
    Lord, Simon
    Moreno, Victor
    Macpherson, Iain R.
    Boni, Valentina
    Rolfo, Christian
    de Vries, Elisabeth G. E.
    Rottey, Sylvie
    Geenen, Jilt
    Eskens, Ferry
    Gil-Martin, Marta
    Mommers, Ellen C.
    Koper, Norbert P.
    Aftimos, Philippe
    LANCET ONCOLOGY, 2019, 20 (08): : 1124 - 1135
  • [2] Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II/II HER2+ breast cancer.
    Limentani, S
    Dorval, T
    White, S
    Curigliano, G
    Campone, M
    Disis, N
    Piccart, M
    Cheever, M
    Gérard, C
    Brichard, VG
    Gauducheau, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 170S - 170S
  • [3] Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2- Advanced Breast Cancer
    Bardia, Aditya
    Modi, Shanu
    Oliveira, Mafalda
    Cortes, Javier
    Campone, Mario
    Ma, Brigette
    Dirix, Luc
    Weise, Amy
    Hewes, Becker
    Diaz-Padilla, Ivan
    Han, Yu
    Deshpande, Priya
    Samant, Tanay S.
    Lorenc, Karen Rodriguez
    He, Wei
    Su, Fei
    Chavez-MacGregor, Mariana
    CLINICAL CANCER RESEARCH, 2020, 26 (24) : 6417 - 6428
  • [4] Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases
    Metzger Filho, O.
    Leone, J. P.
    Li, T.
    Tan-Wasielewski, Z.
    Trippa, L.
    Barry, W. T.
    Younger, J.
    Lawler, E.
    Walker, L.
    Freedman, R. A.
    Tolaney, S. M.
    Krop, I
    Winer, E. P.
    Lin, N. U.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1231 - 1239
  • [5] HS-10352 in hormone receptor-positive, HER2-negative advanced breast cancer: A phase 1 dose-escalation trial
    Ouyang, Quchang
    Wang, Ying
    Zhang, Jian
    Wu, Qiong
    Wei, Hongying
    Li, Chuan
    Qian, Xiaoling
    Hu, Xichun
    CANCER MEDICINE, 2023, 12 (24): : 21849 - 21860
  • [6] Effect of prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2-positive early-stage breast cancer: Phase II CONTROL trial
    Chan, Arlene
    Hurvitz, Sara A.
    Marx, Gavin
    Ruiz-Borrego, Manuel
    Farrell, Cynthia
    Hunt, Daniel
    McCulloch, Leanne
    Chien, A. Jo
    Tripathy, Debu
    Barcenas, Carlos H.
    CANCER RESEARCH, 2020, 80 (04)
  • [7] Phase I dose-escalation and dose-expansion trial of CDK4/6 inhibitor FCN-437c in Chinese female patients with ER+HER2-advanced breast cancer (ABC).
    Zhang, Jian
    Wang, Xiaojia
    Wang, Xian
    Hui, Aimin
    Wu, Zhuli
    Tian, Ling
    Xu, Changjiang
    Yang, Yuchen
    Zhang, Wenjing
    Hu, Xichun
    CANCER RESEARCH, 2021, 81 (13)
  • [8] Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
    Pernas, Sonia
    Martin, Miguel
    Kaufman, Peter A.
    Gil-Martin, Marta
    Gomez Pardo, Patricia
    Lopez-Tarruella, Sara
    Manso, Luis
    Ciruelos, Eva
    Alejandro Perez-Fidalgo, Jose
    Hernando, Cristina
    Ademuyiwa, Foluso O.
    Weilbaecher, Katherine
    Mayer, Ingrid
    Pluard, Timothy J.
    Martinez Garcia, Maria
    Vahdat, Linda
    Perez-Garcia, Jose
    Wach, Achim
    Barker, Debra
    Fung, Samson
    Romagnoli, Barbara
    Cortes, Javier
    LANCET ONCOLOGY, 2018, 19 (06): : 812 - 824
  • [9] Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
    Goss, Paul E.
    Smith, Ian E.
    O'Shaughnessy, Joyce
    Ejlertsen, Bent
    Kaufmann, Manfred
    Boyle, Frances
    Buzdar, Aman U.
    Fumoleau, Pierre
    Gradishar, William
    Martin, Miguel
    Moy, Beverly
    Piccart-Gebhart, Martine
    Pritchard, Kathleen I.
    Lindquist, Deborah
    Chavarri-Guerra, Yanin
    Aktan, Gursel
    Rappold, Erica
    Williams, Lisa S.
    Finkelstein, Dianne M.
    LANCET ONCOLOGY, 2013, 14 (01): : 88 - 96
  • [10] Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
    Konstantinopoulos, Panagiotis A.
    Barry, William T.
    Birrer, Michael
    Westin, Shannon N.
    Cadoo, Karen A.
    Shapiro, Geoffrey, I
    Mayer, Erica L.
    O'Cearbhaill, Roisin E.
    Coleman, Robert L.
    Kochupurakkal, Bose
    Whalen, Christin
    Curtis, Jennifer
    Farooq, Sarah
    Luo, Weixiu
    Eismann, Julia
    Buss, Mary K.
    Aghajanian, Carol
    Mills, Gordon B.
    Palakurthi, Sangeetha
    Kirschmeier, Paul
    Liu, Joyce
    Cantley, Lewis C.
    Kaufmann, Scott H.
    Swisher, Elizabeth M.
    D'Andrea, Alan D.
    Winer, Eric
    Wulf, Gerburg M.
    Matulonis, Ursula A.
    LANCET ONCOLOGY, 2019, 20 (04): : 570 - 580
12345